Vascular grafts are pivotal tools in treating occlusive vascular diseases, yet their long-term success hinges on rapid and complete endothelialization—the process by which endothelial cells line the inner surface of blood vessels. Traditional synthetic grafts suffer from thrombosis and intimal hyperplasia largely due to delayed or incomplete endothelial coverage. Previous efforts to enhance endothelialization focused mostly on modifying graft surface chemistries or pre-seeding with endothelial cells. Despite these interventions, clinical outcomes remain suboptimal, highlighting the need for a deeper understanding of in vivo cellular mechanisms that govern graft integration.

The study team employed cutting-edge bioprinting technologies to fabricate vascular grafts with precise architecture and biochemical properties conducive to cellular colonization. These constructs were engineered to mimic the extracellular matrix composition and mechanical stiffness characteristic of native vessels. Leveraging a sophisticated in vivo murine model, the researchers traced the recruitment and differentiation of circulating endothelial progenitors—immature cells capable of giving rise to mature endothelial cells—highlighting their crucial role in orchestrating graft lining.

What sets this work apart is the elucidation of the communication axis between the perivascular niche—the microenvironment adjacent to blood vessels rich in supporting cells and signaling molecules—and the circulating endothelial progenitors. Using advanced imaging techniques and single-cell transcriptomics, the team identified key paracrine signals and cellular adhesion cascades that facilitate progenitor homing, survival, and differentiation. This crosstalk accelerates the establishment of a functional endothelial monolayer, drastically reducing the window during which grafts are vulnerable to thrombosis.

A pivotal discovery was the identification of a feedback loop wherein endothelial progenitors not only respond to niche-derived signals but also modulate the microenvironment by secreting angiocrine factors. These factors enhance progenitor recruitment and prime the scaffold surface for optimal cell adhesion and proliferation. This dynamic reciprocity challenges the conventional view of vascular niches as passive reservoirs, painting them instead as active participants in vascular regeneration.

Importantly, the researchers leveraged transcriptomic profiling to decode the gene expression changes underpinning progenitor cell activation and differentiation. Key molecular players such as VEGF-A, CXCL12, and Notch signaling components were found to be instrumental in mediating progenitor-endothelial lineage commitment and integration. Modulating these pathways pharmacologically further boosted endothelialization rates, offering a potential therapeutic avenue to complement bioprinted graft implantation.

The integration of endothelial progenitors was validated by immunohistochemical analyses demonstrating the rapid formation of a contiguous and functional endothelial layer, marked by expression of mature endothelial markers such as PECAM-1 and VE-Cadherin. Functional assays confirmed restored barrier function and antithrombotic properties, highlighting the grafts’ biocompatibility and resilience. These findings signal a remarkable step forward in mitigating the complications traditionally associated with vascular implants.

Of particular note was the temporal profile of endothelialization. Where conventional grafts may require weeks or even months to acquire sufficient endothelial coverage, the bioprinted grafts in this study achieved comparable endothelialization within days. This rapid timeline is crucial in dictating clinical success, potentially reducing the need for anticoagulation therapy and minimizing early graft failure.

The research also underscores the significance of the perivascular niche, extending the concept of stem cell niches into the domain of vascular biology. This niche provides essential cues not only for progenitor recruitment but also for maintaining their stemness and guiding differentiation. Perturbing niche signals experimentally confirmed their indispensable role, paving the way for future bioengineering approaches that integrate niche components to enhance graft performance.

Moreover, this work bridges the gap between regenerative biology and biofabrication, demonstrating that the design of vascular grafts must transcend structural mimicry and incorporate biological cues that actively engage host progenitors. This biologically integrated design philosophy sets a new paradigm for future tissue-engineered vascular grafts and potentially other organ systems reliant on rapid cellular incorporation.

The translational potential of this research is immense. Cardiovascular diseases remain the leading cause of morbidity and mortality worldwide, with millions requiring vascular interventions annually. Synthetic and autologous grafts are limited by availability and compatibility issues. Bioprinted grafts that harness the body’s own regenerative capacities herald a new era of personalized vascular medicine, capable of overcoming these limitations and offering longer-lasting, more effective therapies.

While additional studies are needed to scale this approach to larger animal models and subsequently human trials, the mechanistic insights uncovered lay a solid foundation for therapeutic innovation. Future work may also explore combining this strategy with drug delivery systems to further modulate the vascular microenvironment, enhancing engraftment and long-term function.

In summary, the conjunction of bioengineered vascular scaffolds and the endogenous perivascular niche-derived progenitor population constitutes a powerful strategy to achieve rapid and functional endothelialization. This synergy leverages natural regenerative pathways, reducing reliance on exogenous cells and complex pre-conditioning protocols. As the field advances, such innovations could dramatically improve outcomes in cardiovascular surgery and pave the way for next-generation implantable devices.

The implications extend beyond vascular grafts, potentially informing regenerative strategies for all tissues reliant on organized endothelial structures, including organoids, engineered tissues, and synthetic organs. By deciphering and leveraging the cellular crosstalk governing vascular integration, Zhang, Yuan, Yao, and colleagues have opened a transformative frontier in regenerative medicine, combining the precision of additive manufacturing with the elegance of biological systems.

This pioneering work exemplifies the power of interdisciplinary collaboration, uniting materials science, stem cell biology, vascular physiology, and bioengineering. As we step further into an era where synthetic and biological components are seamlessly integrated, such studies underscore the limitless potential of designing implants that not only replace damaged tissues but also activate the body’s inherent capacity for healing and regeneration.

Subject of Research: Rapid endothelialization of 3D-printed vascular grafts through cellular crosstalk between perivascular niche and circulating endothelial progenitors.

Article Title: Rapid endothelialization of printed vascular grafts by perivascular niche-circulating endothelial progenitors crosstalk.

Article References: Zhang, Zq., Yuan, PP., Yao, C. et al. Rapid endothelialization of printed vascular grafts by perivascular niche-circulating endothelial progenitors crosstalk. Nat Commun (2025). https://doi.org/10.1038/s41467-025-68075-8

Image Credits: AI Generated

Atherosclerosis remains a leading cause of morbidity and mortality worldwide, largely driven by the accumulation of lipid-laden macrophages, known as foam cells, within arterial walls. These transformed macrophages contribute to plaque formation, instability, and eventual cardiovascular events. Central to this pathological process is the reprogramming of macrophage metabolism and gene expression, which has spurred intensive research efforts aimed at identifying molecular interventions capable of restoring cellular homeostasis and attenuating inflammatory damage.

The crux of the new study lies in the targeted delivery of microRNA-10a (miR-10a) encapsulated in liposomes, which specifically modulate the metabolic machinery and epigenetic regulators of macrophages implicated in atherosclerotic progression. MicroRNAs, small non-coding RNA molecules, play pivotal roles in post-transcriptional gene silencing and have emerged as potent modulators of immune cell phenotype. By harnessing miR-10a’s regulatory potential, the researchers sought to shift the metabolic state of macrophages from a pro-inflammatory to a reparative, anti-atherogenic profile.

Mitochondrial metabolism is increasingly recognized as a central node in immune cell programming, influencing not only energy production but also the generation of signaling metabolites that dictate epigenetic landscapes. In the context of macrophages, a shift towards oxidative phosphorylation and enhanced mitochondrial function correlates with resolution of inflammation, whereas glycolytic reprogramming promotes sustained pro-inflammatory states. The study demonstrates that miR-10a liposomes restore mitochondrial integrity and bioenergetic capacity, leading to marked reductions in inflammatory cytokine expression and foam cell formation.

Crucially, the therapeutic efficacy of miR-10a was linked to its impact on epigenetic regulators, specifically histone-modifying enzymes that control chromatin accessibility and gene transcription patterns. Through downregulation of key histone deacetylases and methyltransferases, miR-10a facilitated the reactivation of genes involved in lipid metabolism and anti-inflammatory responses. This dual action on mitochondrial function and epigenetic control represents a synergistic mechanism that efficiently reprograms macrophages, attenuating the pathogenic cycle that underpins atherosclerosis.

Liposomes served as a highly effective delivery vehicle, overcoming previous barriers related to stability, cellular uptake, and targeted tissue distribution of RNA therapeutics. Their nanoscale size and biocompatibility enabled precise delivery of miR-10a to macrophages within the atherosclerotic plaque microenvironment. Upon administration in murine models of atherosclerosis, miR-10a liposomes significantly reduced plaque burden and improved arterial function, providing compelling in vivo validation of this strategy.

Beyond plaque regression, the treatment also enhanced systemic metabolic profiles, as evident by improved lipid panels and reduced markers of systemic inflammation. This suggests that metabolic reprogramming of macrophages not only impacts local disease processes but may also confer broader cardiovascular benefits. The findings highlight the interconnectedness of immune cell metabolism and systemic homeostasis, expanding the therapeutic potential of miRNA-based interventions.

This study further contributes to the burgeoning field of immunometabolism, where the metabolic state of immune cells is increasingly appreciated as a determinant of their function and fate. By delineating the precise molecular targets of miR-10a and elucidating its epigenetic effects, the research adds valuable insight to the mechanistic underpinnings that govern macrophage plasticity in chronic inflammatory diseases.

The implications for clinical translation are profound. Current atherosclerosis treatments primarily focus on lipid-lowering therapies and symptomatic management, with limited options for directly modulating inflammatory processes at the cellular level. miRNA-based therapeutics, especially those leveraging advanced delivery systems like liposomes, open new frontiers for precision medicine aimed at reprogramming disease-driving immune cells rather than merely suppressing symptoms.

Nevertheless, several challenges remain before this innovative approach can be brought to the clinic. Long-term safety, dosing regimens, and the potential for off-target effects require meticulous evaluation in preclinical and clinical studies. Moreover, the heterogeneity of macrophage populations and their dynamic roles in various stages of atherosclerosis necessitate careful optimization of treatment timing and combinations with existing therapies.

As the study’s first authors underscore, future directions include investigating the combinatorial effects of miR-10a with other metabolic and epigenetic modulators, as well as extending this strategy to other chronic inflammatory and metabolic conditions. The versatility of miRNA therapeutics encoded within liposomes holds promise to revolutionize a spectrum of diseases where immune cell dysfunction is a key driver.

This research epitomizes the power of interdisciplinary collaboration, marrying molecular biology, nanotechnology, immunology, and metabolism to tackle one of the most pressing public health challenges. It underscores the paradigm shift from traditional pharmacology toward sophisticated gene regulatory therapies tailored to the cellular microenvironment and metabolic state.

In summary, the exploitation of miR-10a-loaded liposomes to reprogram mitochondrial metabolism and epigenetic architecture of macrophages marks a transformative advancement in cardiovascular disease therapy. By correcting the root cause of immune dysregulation in atherosclerosis, this approach offers hope for durable, targeted interventions that move beyond symptom control to fundamentally alter disease trajectory.

The exciting convergence of miRNA biology and lipid nanocarrier technology detailed in this study sets the stage for a new era of smart therapeutics that harness endogenous regulatory circuits to restore health. With further refinement and clinical validation, miR-10a liposomal therapy could become a cornerstone in the fight against atherosclerosis, heralding a future where precision epigenetic reprogramming becomes a standard weapon against chronic inflammation.

As researchers continue to decode the complex crosstalk between metabolism and gene expression in immune cells, miRNA-based interventions exemplify the next-generation tools capable of exploiting this nexus. The promise of this innovative treatment lies not only in its therapeutic efficacy but also in its potential to inspire new lines of inquiry into the metabolic-epigenetic interface across multiple disease domains.

Ultimately, this pioneering work reaffirms the shifting paradigm in biomedical research, where the integration of molecular insights and nanomedicine offers unprecedented opportunities to tackle the root causes of disease at a cellular and epigenetic level. The remarkable efficacy of miR-10a liposomes in modulating macrophage function could pave the way for entirely new classes of therapies designed to re-educate the immune system and restore tissue homeostasis.

With cardiovascular disease continuing to impose a staggering global health burden, advances such as these propel us closer to groundbreaking therapies that blend molecular precision with innovative delivery platforms. This study not only showcases the transformative potential of miRNA therapeutics but also exemplifies the future trajectory of personalized medicine aimed at correcting metabolic and epigenetic aberrancies at their source.

Article References:
Fang, F., Wang, E., Yang, H. et al. Reprogramming mitochondrial metabolism and epigenetics of macrophages via miR-10a liposomes for atherosclerosis therapy. Nat Commun 16, 9117 (2025). https://doi.org/10.1038/s41467-025-64201-8